$ARCT News

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026

Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call

Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19

Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform

Why Is Arcturus Therapeutics Stock Gaining Thursday?

Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20

BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $20

Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform - Slideshow

Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

Arcturus Therapeutics Says ARCT-810 Generally Safe And Well Tolerated, Demonstrating Encouraging Activity Across Key Urea Cycle Biomarkers In Ongoing Phase 2 Study

Arcturus To Acquire myNEO, An AI Discovery Company, To Improve mRNA Design Quality, Accelerate Innovation, And Enhance Target Identification Capability; No Financial Terms Disclosed; Co To Host Presentation At 4:30 p.m. ET today

Arcturus Therapeutics Announces Interim Phase 2 Results From ARCT-810 In OTC Deficienc And Introduces LUNAR 2.0

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

Arcturus Therapeutics To Present Overview Of ARCT-810 Phase 2 Clinical Program For Ornithine Transcarbamylase Deficiency And Arcturus’ mRNA Liver Therapeutics Platform On Sept. 23

Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Arcturus Therapeutics to Participate in Upcoming Investor Conferences

Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

Arcturus Therapeutics Q2 Earnings Call Highlights